HeartFlow, Inc. — Cyborg Score 6/10

Solid

Strategic Profile

HeartFlow's cloud-based, hardware-agnostic platform allows any hospital with a CT scanner to upload images and receive analysis within hours, eliminating upfront capital expenditure and reducing marginal cost per diagnosis. The company is at a reimbursement inflection point with major payer coverage expansions for its Plaque Analysis product, though CMS's proposed 2026 reimbursement cut threatens core FFR CT Analysis revenue.

Cyborg Score Rationale

Strong revenue growth momentum (44% increase in 2024 to $125.8M, 39% YoY in Q1 2025) and recent IPO capital position strengthen the company, but accumulated $1.1 billion deficit and $43.4 million cash burn from operations in 9M 2025 raise profitability concerns despite 75%+ gross margins.

Top Insights

  • Near-monopoly status in AI-driven non-invasive CAD diagnosis with 98% revenue concentration in core FFR CT Analysis product
  • Major payer expansions including Aetna coverage for Plaque Analysis effective December 2025 following similar moves by Cigna and UnitedHealthcare
  • CMS's proposed 15% reimbursement cut for 2026 poses direct revenue risk that could force price reductions and compress margins
  • Expanding clinical applications including GAMEFILM Registry targeting over 300 retired professional athletes to study coronary plaque risk

Named Competitors

  • CT-based FFR Analysis Tools — Traditional imaging equipment manufacturers developing competitive blood flow analysis bundled with hardware
  • Cleerly — FDA-cleared coronary CT analysis software using mobile scanners for underserved communities
  • Myocardial Solutions — Cardiac MRI enhancement for cancer patients at risk of heart damage from treatment

Recent Developments

  • (Feb 2026) GAMEFILM Registry expanded to include NBA and NHL players, building on initial NFL alumni phase
  • (Dec 2025) Aetna coverage expansion for Heartflow Plaque Analysis across Commercial, Medicare Advantage, and Medicaid plans
  • (Aug 2025) IPO closed at $364M valuation, initiating NASDAQ trading under HTFL symbol
  • (Q3 2025) 41% YoY revenue growth to $46.3M with continued insurance coverage expansions

Open the full interactive HeartFlow, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →